Group items tagged

The global anti-obesity Drugs Market is segmented in by product:-Peripherally acting anti-obesity agents, centrally acting anti-obesity drugs; by mode of action:-Fat Absorption Inhibition, Food Intake Suppression:- Noradrenergic Drugs, Serotoninergic Drugs, Adrenergic Drug, Others; Increase Thermogenesis; Segmentation by Type:- Prescription Drugs, Over the Counter Drugs; Segmentation by Distribution Channel:- Hospital Pharmacy, Retail Pharmacy and by regions. Anti-Obesity Drugs Market is anticipated to mask a significant CAGR during the forecast period i.e. 2015-2021. Anti-obesity drugs are pharmacological agents that are used to lose cholesterol and reduce the body weight. These drugs generally show their action by altering the fundamental functioning of the normal body by utilization of calories or by altering the appetite. The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

The Department of Health (DoH) is inviting the public to share their views on a new Regional Obesity Management Service and a new Obesity Strategic Framework. A public consultation has been launched on the Healthy Futures strategic framework, which aims to prevent the harm caused by obesity, and improve diets and levels of physical activity of people. The Department is also seeking views on its plans to introduce a new service that would focus on the introduction of specialist support, weight loss medication, and bariatric surgery to help people living with obesity. Northern Ireland is seeing an increase in obesity rates, with the latest Health Survey NI data showing that 65 per cent of adults and 26 per cent of children in the country are either obese or overweight.

The Disease They Call FAT is best solutions and treatment for Obesity in New York and surrounding the area. This film introduces us to a disease hiding in plain sight, and makes a compelling case that it is time to end the suffering.

A roundtable organised by National Pharmacists Association (NPA) discussed how an enhanced role of community pharmacies could help people with obesity. Seven action points were recommended by the delegates at the virtual event which took place on March 31, in collaboration with Novo Nordisk. It was chaired by Professor Maggie Rae, president of the Faculty of Public Health and featured representatives from the Royal Pharmaceutical Society, Royal Society for Public Health, Patients Association, UK Health Security Agency, Diabetes UK and NHS England. The roundtable also heard testimony from a parent of a young adult living with obesity and a presentation of the personal experience of someone living with the condition by Sarah Le Brocq, director of campaign group, All About Obesity.

A recent study presented at the European Congress on Obesity in Venice sheds light on the detrimental effects of obesity on workplace absenteeism and economic productivity. The analysis, encompassing data from millions of workers across Europe, reveals a direct correlation between body mass index (BMI) and the likelihood of taking sick leave. According to the study, obese individuals are up to twice as likely to take time off work due to health issues compared to those of a healthy weight. The increased sick notes among obese individuals is attributed to various complications associated with obesity, including joint pain, diabetes, depression, and heart disease. In the United Kingdom, where obesity rates are among the highest in Europe, the impact of obesity on workplace absenteeism is particularly pronounced.

A new analysis says that fat ladies who smoke cigarettes might not have the interest towards sweets.

Lipedema is a fat disorder that is under-recognized and often misdiagnosed. It is painful, debilitating, and left untreated results in immobility.

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to 19 per cent weight loss after 46 weeks in a mid-stage trial. The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation. Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called glucagon that helps break down fat.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

Japanese researchers at Okayama University have found that paternal high-fat diet (HFD) intake may lead to a number of changes in next generations including generational obesity and metabolic dysfunction. But, if the next two generations are given controlled diet, the metabolic effects of grand paternal high-fat diet may be diminished.

A new research has suggested that meat contributes to the growing global obesity prevalence as much as sugar and moreover it is protein, not the fat present in meat which is a major obesity contributor. Proteins digest slow as compared to fats Carbohydrates and fats not only provide us with enough energy, the body demands, they are also digested faster than protein.

Obesity and Diabetes: A new study has found that twins having higher body mass index (BMI) have increased risk of developing type 2 diabetes.

The program's overall goal is to give practices the motivation, support, and infrastructure needed to deliver coordinated, high-quality care within the current work environment. Initially, the Blueprint model was pilot tested in three areas and now serves more than half the state's residents in 14 communities. Early trends in the pilot communities suggest that the program has reduced utilization and growth in health care spending and improved the provision of appropriate care and services.

These days, there are many young women who consume alcohol in their daily routine. They are hardly aware of the fact that it might be raising their risk of breast cancer, as stated by U.S. research published.

Less time spent in watching Tv leads to better school results

Fatty Liver Diet Guide Reveals Powerful Treatment of Fatty Liver Disease